• Something wrong with this record ?

MicroRNAs: Emerging Regulators of Immune-Mediated Diseases

T. Tomankova, M. Petrek, J. Gallo, E. Kriegova,

. 2012 ; 75 (2) : 129-141.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Grant support
NT11117 MZ0 CEP Register

E-resources Online Full text

NLK Free Medical Journals from 1997 to 1 year ago
Medline Complete (EBSCOhost) from 1972-01-01 to 1 year ago
Wiley Online Library (archiv) from 1997-01-01 to 2012-12-31
Wiley Free Content from 1997 to 1 year ago

MicroRNAs (miRNAs) represent the most abundant class of regulators of gene expression in humans: they regulate one-third of human protein-coding genes. These small noncoding ∼22-nucleotides (nt)-long RNAs originate by multistep process from miRNA genes localized in the genomic DNA. To date, more than 1420 miRNAs have been identified in humans (miRBase v17). The main mechanism of miRNA action is the posttranscriptional regulation via RNA interference with their target mRNAs. The majority of target mRNAs (more than 80%) undergo degradation after recognition by complementary miRNA; the translational inhibition with little or no influence on mRNA levels has been also reported. Each miRNA may suppress multiple mRNA targets (average ∼200), and at the same time, one mRNA can be targeted by many miRNAs enabling to control a spectrum wide range of cellular processes. Recently, the role of miRNAs in the development of immune cells and the maintenance of immune system homeostasis gained attention, and the involvement of miRNAs in the pathogenesis of several immune system diseases has emerged. This review focuses on the role of miRNAs in autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and psoriasis), inflammatory pathologies of distinct organ (atherosclerosis, osteoarthritis and atopic eczema) and/or systemic locations such as allergy. The role of miRNAs, their predicted and known mRNA targets and description of their actions in physiological immune reactions and in the pathological processes ongoing in immune-mediated human disorders will be discussed. Finally, miRNA-based diagnostics and therapeutic potentials will be highlighted.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15032125
003      
CZ-PrNML
005      
20190606100005.0
007      
ta
008      
151005s2012 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/j.1365-3083.2011.02650.x $2 doi
035    __
$a (PubMed)21988491
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tománková, Tereza $u Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic $7 xx0199224
245    10
$a MicroRNAs: Emerging Regulators of Immune-Mediated Diseases / $c T. Tomankova, M. Petrek, J. Gallo, E. Kriegova,
520    9_
$a MicroRNAs (miRNAs) represent the most abundant class of regulators of gene expression in humans: they regulate one-third of human protein-coding genes. These small noncoding ∼22-nucleotides (nt)-long RNAs originate by multistep process from miRNA genes localized in the genomic DNA. To date, more than 1420 miRNAs have been identified in humans (miRBase v17). The main mechanism of miRNA action is the posttranscriptional regulation via RNA interference with their target mRNAs. The majority of target mRNAs (more than 80%) undergo degradation after recognition by complementary miRNA; the translational inhibition with little or no influence on mRNA levels has been also reported. Each miRNA may suppress multiple mRNA targets (average ∼200), and at the same time, one mRNA can be targeted by many miRNAs enabling to control a spectrum wide range of cellular processes. Recently, the role of miRNAs in the development of immune cells and the maintenance of immune system homeostasis gained attention, and the involvement of miRNAs in the pathogenesis of several immune system diseases has emerged. This review focuses on the role of miRNAs in autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and psoriasis), inflammatory pathologies of distinct organ (atherosclerosis, osteoarthritis and atopic eczema) and/or systemic locations such as allergy. The role of miRNAs, their predicted and known mRNA targets and description of their actions in physiological immune reactions and in the pathological processes ongoing in immune-mediated human disorders will be discussed. Finally, miRNA-based diagnostics and therapeutic potentials will be highlighted.
650    _2
$a revmatoidní artritida $x genetika $x imunologie $x patologie $7 D001172
650    _2
$a ateroskleróza $x genetika $x imunologie $x patologie $7 D050197
650    _2
$a atopická dermatitida $x genetika $x imunologie $x patologie $7 D003876
650    _2
$a epigeneze genetická $x imunologie $7 D044127
650    _2
$a lidé $7 D006801
650    _2
$a přirozená imunita $7 D007113
650    _2
$a idiopatické střevní záněty $x genetika $x imunologie $x patologie $7 D015212
650    _2
$a systémový lupus erythematodes $x genetika $x imunologie $x patologie $7 D008180
650    _2
$a mikro RNA $x genetika $x imunologie $7 D035683
650    _2
$a roztroušená skleróza $x genetika $x imunologie $x patologie $7 D009103
650    _2
$a osteoartróza $x genetika $x imunologie $x patologie $7 D010003
650    _2
$a psoriáza $x genetika $x imunologie $x patologie $7 D011565
650    _2
$a RNA interference $x imunologie $7 D034622
650    _2
$a stabilita RNA $7 D020871
650    _2
$a messenger RNA $x genetika $x imunologie $7 D012333
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Petrek, M $u Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech RepublicDepartment of Orthopaedics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Gallo, Jiří $u Department of Orthopaedics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. $7 xx0019005
700    1_
$a Kriegová, Eva, $u Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic $d 1968- $7 xx0142572
773    0_
$w MED00010600 $t Scandinavian journal of immunology $x 1365-3083 $g Roč. 75, č. 2 (2012), s. 129-141
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21988491 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20190606100142 $b ABA008
999    __
$a ok $b bmc $g 1093001 $s 915251
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 75 $c 2 $d 129-141 $i 1365-3083 $m Scandinavian journal of immunology $n Scand J Immunol $x MED00010600
GRA    __
$a NT11117 $p MZ0
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...